Home / Going-concern warnings / Oncotelic Therapeutics, Inc.
Filed 2025-04-15 路 Form 10-K 路 Accession 0001641172-25-004846 nano
Price before filing: $0.0559 (2025-04-14 close, split/dividend-adjusted)
Market cap at flag: $21.0M (2025-04-15) 路 Latest: $7.4M (2026-10-16)
| Window | OTLC | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -1.4% | +9.5% | -11.0% | 2025-05-15 |
| 90 days | +3.8% | +16.2% | -12.5% | 2025-07-14 |
| 180 days | +57.7% | +23.7% | +34.0% | 2025-10-13 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 1 insider bought $10K (3 purchases)
30 days after: none reported.
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2025-01-29 | Trieu Vuong CHAIRMAN AND CEO, Director, 10% owner | Purchase | 183,066 | $0.03 | $5K | no | Form 4 |
| 2025-01-30 | Trieu Vuong CHAIRMAN AND CEO, Director, 10% owner | Purchase | 100,003 | $0.03 | $3K | no | Form 4 |
| 2025-01-31 | Trieu Vuong CHAIRMAN AND CEO, Director, 10% owner | Purchase | 63,775 | $0.03 | $2K | no | Form 4 |
| 2025-04-15: red flag filed | |||||||
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-01-15 to 2025-05-15. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and has an accumulated deficit and a working capital deficiency that raise substantial doubt about its ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Going-concern opinion issued by: Rose, Snyder & Jacobs LLP
Source: independent auditor report in Form 10-K (period 2024-12-31)
Why this score: in auditor's report
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.